基于体内成分与代谢标记物相关联的少腹逐瘀汤治疗寒凝血瘀证子宫内膜异位症配伍规律研究

少腹逐瘀汤是治疗寒凝血瘀证子宫内膜异位症（EMs）的经典方剂，临床疗效确切，但方剂配伍规律尚未阐明。本项目在少腹逐瘀汤治疗EMs前期研究基础上，进一步采用符合中医整体观的代谢组学方法，同时结合中药血清药物化学理论①制备寒凝血瘀证EMs大鼠模型，以代谢组学方法分析造模前后及造模过程中体液的代谢物谱变化，挖掘病症的代谢标记物，描述相关代谢经路；②在此基础上，应用少腹逐瘀汤对病症结合大鼠模型进行干预，观察代谢标记物的变化，并研究组方药物配伍对少腹逐瘀汤干预作用的影响；③同时应用血清药物化学方法，分析少腹逐瘀汤体外物质基础和入血成分及配伍对其影响；④最后，将体内成分与代谢标记物相关联，考察配伍与之相关性；最终从体外物质基础、体内成分、代谢标记物及体内成分与代谢标记物关联性四个角度阐明少腹逐瘀汤配伍的科学内涵；同时，探索以“体内成分—代谢标记物”相关联的方剂配伍规律研究新模式。

Shaofuzhuyu Tang (ST) is a classic recipe for the treatment of Endometriosis (EMs) with cold blood stasis syndrome. In spite of clinical efficacy is clear, but the prescription compatibility law has not been elucidated. On the basis of pre-experimental studies on the ST for the treatment of EMs, the project will be further use metabolomics methods consistent with the overall concept of traditional Chinese medicine, combined with theory of TCM Serum Pharmacochemistry, the preparation rats model EMs of cold blood stasis syndrome, analysis changes of metabolite profiling of process modeling, mining metabolic markers of EMs disorders and metabolism pathways. On this basis of that, the application ST intervention on rat model of EMs disease, observed changes in metabolism markers, and to study the prescription combined drugs impact on ST; while using Serum Pharmacochemistry method to analyze ST material foundation and into the blood components and its compatibility. Finally, the correlation of body composition and metabolic markers is to investigate the compatibility; ultimately from the body composition, metabolic markers and both illustrate the scientific connotation of relevance; at the same time, to explore new model of ‘body composition - metabolic markers’ associated with prescription compatibility law research.